GLP-1 Receptor Agonists for Weight Loss in People without Type …
WEBMay 12, 2023 — The evidence supporting the use of GLP-1 RAs for weight loss in nondiabetic individuals is still evolving, and our knowledge is more limited compared to the benefits in patients with type 2 diabetes.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
WEBNov 11, 2023 — Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with...
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive …
WEBJun 21, 2023 — GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss.
Efficacy of GLP-1 Agonists for Weight Loss in Adults Without Diabetes
WEBJun 16, 2022 — The new indications include weight loss in adults with obesity (body mass index [BMI] ≥30) without diabetes and adults with a BMI ≥27 and 1 weight-related comorbidity (hypertension, type 2 ...
Efficacy of GLP-1 RA Approved for Weight Management in …
WEBMay 3, 2022 — The mean weight loss difference between GLP-1 RAs and placebo as add-on to lifestyle intervention in patients with diabetes was 4% to 6.2% compared to 6.1 to 17.4% in people without diabetes. Semaglutide compared to …
A Balancing Act: GLP-1 Receptor Agonists for Non-Diabetic Obesity
WEBDec 29, 2020 — GLP-1 agonists are a promising drug class originally developed for the treatment of type 2 diabetes, but recently shown to be effective for weight loss in non-diabetic patients with obesity or overweight BMI when given as adjunctive therapy to diet and exercise. 8 Endogenous glucagon-like peptide-1 (GLP-1) is …
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 …
WEBThe present study provides conclusive evidence for the effect of GLP-1RAs on weight loss in a nonlinear dose-response manner in patients with obesity or overweight without diabetes. In terms of changes in BW, BMI, and WC, there is firm evidence for the overall weight-loss effects of GLP-1RAs.
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 …
WEBThe present study provides conclusive evidence for the effect of GLP-1RAs on weight loss in a nonlinear dose-response manner in patients with obesity or overweight without diabetes. In terms of changes in BW, BMI, and WC, there is firm evidence for the overall weight-loss effects of GLP-1RAs.
WEBGLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study. Hannah Moll,a,f Eliane Frey,b,f Philipp Gerber,c Bettina Geidl,c Marco Kaufmann,a Julia Braun,a Felix Beuschlein,c,d,e Milo A. Puhan,a and Henock G. Yebyoa,∗.
Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for ...
WEBJul 21, 2024 — The review concludes that glucagon-like peptide agents act as pharmacologic treatments for reduction in body weight and also serve as cardioprotective agents. Keywords: diabetes; endocrinology; glucagon-like peptide receptor agonists; obesity; weight loss.